RFX2

Across TCGA pan-cancer cohorts, RFX2 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of RFX2’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where RFX2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types RFX2 is over-expressed in tumor, although a few such as LUAD and LSCC show the opposite, repressed pattern.

LUAD, LSCC, and HNSC are the cancer types where RFX2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RFX2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Female	III,IV	−0.670	<.001	9	view →
LSCC	Female	All	−0.731	<.001	8	view →
HNSC	All	III,IV	−0.328	<.001	8	view →
CCRCC	Male	All	+0.718	<.001	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

RFX2–LUAD

Open the LUAD breakdown →